Genome‐wide mutation analysis in precancerous lesions of endometrial carcinoma
- 5 October 2020
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 253 (1) , 119-128
Abstract
Clinicopathological evidence supports endometrial atypical hyperplasia (AH) or endometrial intraepithelial neoplasia as the precursor of uterine endometrioid carcinoma (EC), the most common gynecologic malignancy. However, the pathogenic progression from AH to EC remains unclear. Here, we employed whole‐exome sequencing to identify somatic mutations and copy number changes in micro‐dissected lesions from 30 pairs of newly diagnosed AH and EC. We found that all but one pair of AHs shared the same DNA mismatch repair status as their corresponding ECs. The percentage of common mutations between AH lesions and corresponding ECs varied significantly, ranging from 0.1% to 82%. Microsatellite stable AHs had fewer cancer driver mutations than ECs (5 versus 7, p = 0.017), but among microsatellite unstable AHs and ECs there was no difference in mutational numbers (36 versus 38, p = 0.65). As compared to AH specimens, 19 (79%) of 24 microsatellite stable EC tumors gained new cancer driver mutations, most of which involved PTEN , ARID1A , PIK3CA , CTNNB1 , or CHD4 . Our results suggest that some AH lesions are the immediate precursor of ECs, and progression depends on acquisition of additional cancer driver mutations. However, a complex clonal relationship between AH and EC can also be appreciated, as in some cases both lesions diverge very early or arise independently, thus co‐developing with distinct genetic trajectories. Our genome‐wide profile of mutations in AH and EC shines new light on the molecular landscape of tumor progression. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 40 references indexed in Scilit:
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetateOncology Letters, 2012
- PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial CancerCancer Research, 2011
- Somatic Mutations of PPP2R1A in Ovarian and Uterine CarcinomasThe American Journal of Pathology, 2011
- Integrative genomics viewerNature Biotechnology, 2011
- Absolute Risk of Endometrial Carcinoma During 20-Year Follow-Up Among Women With Endometrial HyperplasiaJournal of Clinical Oncology, 2010
- Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistanceLaboratory Investigation, 2009
- Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsiesCancer, 2008
- Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health planBritish Journal of Cancer, 2007
- Concomitant Endometrial Hyperplasia in Patients with Endometrial CarcinomaGynecologic Oncology, 1998